# Open Label Safety Study in Acute Treatment of Migraine

> **NCT03266588** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 3019 (actual)

## Conditions studied

- Migraine, With or Without Aura

## Interventions

- **DRUG:** Rimegepant

## Key facts

- **NCT ID:** NCT03266588
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-30
- **Primary completion:** 2019-07-15
- **Final completion:** 2019-07-15
- **Target enrollment:** 3019 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03266588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03266588, "Open Label Safety Study in Acute Treatment of Migraine". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03266588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*